Submitted:
31 December 2024
Posted:
03 January 2025
You are already at the latest version
Abstract
Liposomal drug delivery systems are one of the most promising innovations to revolutionize this pharmaceutical industry. It incorporates drugs with hydrophilic as well as hydrophobic properties into a biocompatible lipid bilayer. In this review, general properties of liposomes will be discussed, including composition and mechanisms involved in the augmentation of drug solubility, stability, and targeted delivery. It referred to the development of liposomal formulations and important milestones, such as the FDA approval of Doxil, as the turning points in the clinical application of liposomes. It has been used in the therapeutic field of oncology where the systemic toxicity reduces simultaneously while making the therapy more effective. Also emphasized in this paper are the advantages of liposomal systems, sustained release profiles, and combination therapies that can help against the problem of drug resistance. A further review of the current clinical applications of liposomes is advanced in order to show successful products which have, indeed, impacted the treatment of a patient. There's a good scope for the integration of liposomal technology with novel therapeutic strategies and it's in this direction that the mandate of treating more effectively and personalizing treatment may be considered. The review focuses on the critical role of liposomal drug delivery systems in modern medicine, underlining their potential to revolutionize therapeutic approaches and patient outcomes.
Keywords:
1. Introduction to Liposomes
1.1. Definition and Structure of Liposomes
| S. No. | Factor | Description | References |
| 1 | Size of Liposomes | Liposomes range from 50 nm to several micrometers. Size affects pharmacokinetics, distribution, and cellular uptake. | [3,4] |
| 2 | Tissue Penetration | Smaller liposomes penetrate tissues more effectively, enhancing cellular uptake. | [3] |
| 3 | Larger Liposomes | Larger liposomes are better suited for delivering larger molecules or prolonged circulation in the bloodstream. | [4] |
| S. No. | Factor | Description | References |
| 1 | Surface Characteristics | Modifying surface characteristics (charge and hydrophilicity) improves stability and targeting. | [3,4] |
| 2 | PEGylation | PEG incorporation prolongs circulation time in the bloodstream, enhancing the therapeutic efficacy of drugs. | [3,4] |
1.2. Historical Context
1.3. Importance in Modern Medicine
| S. No. | Factor | Description |
| 1 | Improved Solubility & Stability | Liposomal formulations enhance the solubility, stability, and bioavailability of therapeutic agents. |
| 2 | Oncology Applications | Liposomes are particularly useful in oncology for targeting chemotherapeutic agents directly to tumor sites, improving efficacy and reducing systemic toxicity. |
| 3 | Reduced Systemic Toxicity | Targeted drug delivery to tumors reduces the impact on healthy tissues, thereby lowering systemic toxicity. |
| 4 | Enhanced Efficacy in Cancer | Liposomal formulations improve therapeutic outcomes by ensuring more effective drug targeting to cancer cells. |
2. Mechanisms of Liposomal Drug Delivery
2.1. Mechanisms of Action
2.2. Advantages Over Traditional Drug Delivery Methods
2.3. Current Clinical Applications
3. Final Thoughts
| S. No. | Factor | Description | References |
| 1 | Benefits over Traditional Methods | Liposomal drug delivery systems improve solubility, stability, and bioavailability of a wide range of therapeutic agents. | [21] |
| 2 | FDA Approval & Impact on Oncology | Doxil® was the first FDA-approved nano-drug, setting a precedent for the clinical application of liposomal formulations in oncology. | [22] |
| 3 | Clinical Success & Reduced Toxicity | Liposomal formulations like AmBisome® improve therapeutic efficacy while minimizing toxicity. | [30] |
| 4 | Versatility in Clinical Applications | Liposomal systems have evolved from concept to clinical use, showcasing their adaptability in addressing medical challenges. | [30] |
| 5 | Ongoing Research & Innovation | Continuous advancements in liposomal formulations are being made for targeted delivery and combination therapies. | [33] |
| 6 | Potential for Personalized Medicine | Liposomes have the potential to enhance personalized medicine by tailoring treatments to individual patient needs. | [33,34] |
| 7 | Integration with Emerging Technologies | The combination of liposomes and nanotechnology may lead to safer, more effective therapies. | [28] |
4. Conclusions
References
- Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. International Journal of Research Publication and Reviews, 4(8), 1379-1384. ISSN 2582-7421.
- Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. World Journal of Pharmaceutical Research, 13(13), 1155-1169. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. World Journal of Pharmaceutical Research, 13(13), 1243-1262.
- Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. [CrossRef]
- Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World Journal of Pharmaceutical Research, 13(13), 1112-1140.
- Gabizon, A., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 42(5), 419-436. [CrossRef]
- Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. World Journal of Pharmaceutical Research, 13(16), 176-189.
- Reddy, L. H., & Reddy, S. M. (2011). Lip osomal drug delivery systems: A review of their applications and potential. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Allen, T. M. (2002). Liposomes: Opportunities in drug delivery. Drugs of the Future, 27(1), 1-10. [CrossRef]
- Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347. [CrossRef]
- Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
- Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Torchilin, V. P. (2007). Micelles from lipid-core micelles to liposomes: A new approach to drug delivery. Drug Delivery, 14(1), 1-10. [CrossRef]
- Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. [CrossRef]
- Sengar, A., Yadav, S., & Niranjan, S. K. (2024). Formulation and evaluation of mouth-dissolving films of propranolol hydrochloride. World Journal of Pharmaceutical Research, 13(16), 850-861.
- Sengar, A., Tile, S. A., Sen, A., Malunjkar, S. P., Bhagat, D. T., & Thete, A. K. (2024). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. World Journal of Pharmaceutical Research, 13(18), 1424-1435.
- Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347. [CrossRef]
- Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
- Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin:From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. World Journal of Pharmaceutical Research, 13(21), 1063-1071.
- Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Sengar, A. (2024). Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. Preprints. [CrossRef]
- Sengar, A. (2024). Liposomes and Beyond: Pioneering Vesicular Systems for Drug Delivery. Preprints. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).